focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: -2.00 (-8.89%)
Spread: 1.00 (5.00%)
Open: 22.50
High: 23.50
Low: 20.50
Prev. Close: 22.50
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

3 Nov 2020 14:54

RNS Number : 1387E
Angle PLC
03 November 2020
 

ANGLE plc

("ANGLE" or "the Company")

 

Director/PDMR Dealings

 

 

ANGLE plc (AIM: AGL OTCQX: ANPCY), a world leading liquid biopsy company, has been notified that the following Directors of the Company purchased ordinary shares of 10 pence each in the Company ("Ordinary Shares") on 2 November 2020:

 

- Ian Griffiths, Finance Director of the Company, purchased 30,000 Ordinary Shares at a price of 44.75 pence per Ordinary Share. Following this purchase Mr. Griffiths is beneficially interested in a total of 703,832 Ordinary Shares, representing approximately 0.41 per cent of the Company's currently issued share capital; and

 

- Garth Selvey, Non-Executive Chairman of the Company, purchased 30,000 Ordinary Shares at a price of 45.00 pence per Ordinary Share. Following this purchase Mr. Selvey is beneficially interested in a total of 50,000 Ordinary Shares, representing approximately 0.03 per cent of the Company's currently issued share capital.

 

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.

 

 

For further information ANGLE:

 

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance - Carl Holmes, Simon Hicks, Teddy Whiley

ECM - Alice Lane, Sunila de Silva

 

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

 

+44 (0) 203 705 9330

 

 

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

 

+44 (0) 203 727 1000

+1 212 850 5624

 

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

Name

 

 

Ian Griffiths

2

Reason for the notification

 

 

a)

Position/status

 

 

Finance Director

b) 

Initial notification /Amendment

 

 

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

Name

 

 

ANGLE plc

b)

LEI

 

 

213800BY11K6W3NMS374

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 10p each 

 

 

GB0034330679

b)

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

 

 Price(s) 

Volume(s)

44.75p 

30,000

d)

Aggregated information

- Aggregated volume

- Price

 

 

Purchase of 30,000 Ordinary Shares at 44.75p per Ordinary Share

e)

Date of the transaction

 

 

2 November 2020

f)

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

 

a)

Name

 

 

Garth Selvey

2

Reason for the notification

 

 

a)

Position/status 

 

 

Non-Executive Chairman

b) 

Initial notification /Amendment 

 

 

Initial notification

3 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

 

a)

Name 

 

 

ANGLE plc

b)

LEI

 

 

213800BY11K6W3NMS374

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

 

 

a)

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary shares of 10p each 

 

 

GB0034330679

b)

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 

 

 

 Price(s) 

Volume(s)

45.00p 

30,000

d)

Aggregated information

- Aggregated volume

- Price

 

 

Purchase of 30,000 Ordinary Shares at 45.00p per Ordinary Share

e)

Date of the transaction

 

 

2 November 2020

f)

Place of the transaction

 

 

London Stock Exchange, AIM Market (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZXLFBBFLEFBX
Date   Source Headline
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.